742 related articles for article (PubMed ID: 25278454)
1. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Sugar EA; O'Dwyer PJ; Ramanathan RK; Von Hoff DD; Rasheed Z; Zheng L; Begum A; Anders R; Maitra A; McAllister F; Rajeshkumar NV; Yabuuchi S; de Wilde RF; Batukbhai B; Sahin I; Laheru DA
Br J Cancer; 2020 Feb; 122(4):498-505. PubMed ID: 31857726
[TBL] [Abstract][Full Text] [Related]
4. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
5. Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas.
Bahra M; Kamphues C; Boas-Knoop S; Lippert S; Esendik U; Schüller U; Hartmann W; Waha A; Neuhaus P; Heppner F; Pietsch T; Koch A
Pancreas; 2012 Mar; 41(2):222-9. PubMed ID: 22076568
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.
Singh BN; Fu J; Srivastava RK; Shankar S
PLoS One; 2011; 6(11):e27306. PubMed ID: 22087285
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Carr RM; Duma N; McCleary-Wheeler AL; Almada LL; Marks DL; Graham RP; Smyrk TC; Lowe V; Borad MJ; Kim G; Johnson GB; Allred JB; Yin J; Lim VS; Bekaii-Saab T; Ma WW; Erlichman C; Adjei AA; Fernandez-Zapico ME
Pancreatology; 2020 Sep; 20(6):1115-1122. PubMed ID: 32778368
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
11. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Calomme A; Demetter P; Delpero JR; Svrcek M; Cros J; Bardier-Dupas A; Puleo F; Monges G; Hammel P; Louvet C; Paye F; Bachelier P; Le Treut YP; Vaillant JC; Sauvanet A; André T; Salmon I; Devière J; Emile JF; Van Laethem JL
Clin Cancer Res; 2015 Mar; 21(5):1215-24. PubMed ID: 25552484
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Dragovich T; Laheru D; Dayyani F; Bolejack V; Smith L; Seng J; Burris H; Rosen P; Hidalgo M; Ritch P; Baker AF; Raghunand N; Crowley J; Von Hoff DD
Cancer Chemother Pharmacol; 2014 Aug; 74(2):379-87. PubMed ID: 24939212
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Zhen DB; Griffith KA; Ruch JM; Camphausen K; Savage JE; Kim EJ; Sahai V; Simeone DM; Zalupski MM
Invest New Drugs; 2016 Dec; 34(6):733-739. PubMed ID: 27439894
[TBL] [Abstract][Full Text] [Related]
16. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
18. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Alberts SR; Foster NR; Morton RF; Kugler J; Schaefer P; Wiesenfeld M; Fitch TR; Steen P; Kim GP; Gill S
Ann Oncol; 2005 Oct; 16(10):1654-61. PubMed ID: 16085692
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
